Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evidence-based treatment during the SARS-CoV-2 pandemic: Identifying the knowns and unknowns of nebulization

J. Andrew Woods

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic with important associated considerations to public health. Among these considerations is the optimal delivery of inhaled bronchodilators to maximize patient care while minimizing SARS-CoV-2 transmission. The potential risk of SARS-CoV-2 transmission through aerosolized respiratory droplets during nebulized treatment of patients with COVID-19 is a currently unsubstantiated concern that has served as the primary driver of a steep increase in the dispensing of albuterol metered-dose inhalers (MDIs). This, in turn, has led to issues obtaining adequate supplies of albuterol MDIs in some parts of the United States.1

To date, there is a lack of data available to determine whether nebulization may generate potentially infectious aerosols. As a result, evidence against the use of nebulization should be interpreted with caution. A recent publication in the New England Journal of Medicine has shown aerosol stability of SARS-CoV-2. However, aerosols in this study were generated under laboratory conditions and may not be applicable to a clinical setting.2 Studies in hospital settings in Singapore and Hong Kong did not provide any direct evidence that patients who were symptomatic with COVID-19 were the source of viral RNA in analyzed air samples.3,4 The first U.S. case of community-acquired COVID-19 was confirmed in a patient hospitalized in California. This patient was not suspected to have COVID-19 at the time of hospitalization and had several aerosol-generating procedures, including nebulization. Of the 121 health care providers (HCPs) exposed to the patient with COVID-19, 43 were symptomatic and were tested for SARS-CoV-2 and 3 tested positive for COVID-19. None of the 3 HCPs wore personal protective equipment when in contact with the patient; therefore, it is difficult to determine with certainty if viral transmission and nebulization were linked.5 A recent study in 4 Wuhan hospitals assessed the protective effects of personal protective equipment for 420 HCPs who provided care to patients with COVID-19 and were involved in aerosol-generating procedures. Despite a high risk of exposure, no HCPs contracted SARS-CoV-2.6

Regarding data relating to SARS-CoV transmission and nebulization, it was not possible to identify if the viral transmission came from the nebulizer itself or if the viral droplets were generated by the patient in one study investigating the temporal and spatial relationship of airborne droplets to patients with SARS-CoV-2.7 Furthermore, a 2004 study using polymerase chain reaction assay of air samples around a patient with SARS-CoV undergoing nebulized treatment found no evidence of virus-specific nucleic acids.8 A 2012 review article on aerosol-generating procedures concluded that there was no evidence of SARS-CoV transmission risk related to
A review of the literature suggested that there is a lack of clear evidence to suggest that nebulized treatment transmits SARS-CoV-2 particles.

Based on the lack of evidence, health care providers should critically evaluate the available data and exercise clinical judgment when considering treatment for patients.

Furthermore, HCPs should take the necessary precautions to minimize the risk of infection.